08 Oct Applications to Open for the Statewide “Innovation to Commercialization Pipeline” Program
ICP Program Will Position Wisconsin Biohealth Startups for Increased Capital Attraction and Scalability
Madison, WI – October 8, 2025: Forward BIOLABS, in partnership with BioForward Wisconsin, is proud to announce the launch of the Innovation to Commercialization Pipeline (ICP) program, a first-of-its-kind statewide initiative designed to help early-stage biohealth companies across Wisconsin navigate the complex journey from discovery to market.
The ICP program aims to overcome critical commercialization barriers and capital-access gaps by providing emerging companies with the tools, resources, and vital support they need to scale. Eligible companies can apply for tailored, company-specific support designed to accelerate their commercialization journey, empowering them to reduce risks and attract future investment. Emerging companies from across the domain of biohealth, such as Biomedical Research & Testing, Biopharmaceuticals, Diagnostics, Digital Health & Software, Health & Wellness Solutions, Life Sciences, Medical Devices, Reagents, Tools & Instrumentation, are encouraged to apply.
“In developing the program, we consistently heard from leaders how essential it is for young companies to be prepared not only to raise seed funding but also to position themselves for larger, follow-on investment,” said Jessica Martin Eckerly, CEO and Co-founder of Forward BIOLABS. “To succeed, these emerging companies need support to hit key milestones that help them secure initial investment from Wisconsin’s early-stage investors, and continued support to bridge the gap in attracting additional capital from investors nationwide. The ICP program was created to help close these gaps and position Wisconsin’s biohealth companies for growth.”